Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples